Causal associations between salt intake with body mass, shape and composition:

A two-sample Mendelian randomization study

Qi FENG PhD [1], Shuai YUAN MD [2], Qian YANG MPhil [3,4], Yingchang LU PhD [5], Ruth J.F. Loos PhD [6], Gloria H.Y. LI PhD [7], Yue FEI PhD [1], Man Fung TSOI PhD [1], Ching Lung CHEUNG PhD [7], Bernard M.Y. CHEUNG PhD [1,8,9]

1. Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China (QF, YF, MFT, BMYC)

2. Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden (SY)

3. Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK (QY)

4. Population Health Sciences, University of Bristol, Bristol, UK (QY)

5. Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, US (YL)

6. The Charles Bronfman Institute for Personalized Medicine at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, US (RJFL)

7. Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China (GHYL, CLC)

8. State Key Laboratory of Pharmaceutical Biotechnology, the University of Hong Kong, Pokfulam, Hong Kong, China (BMYC)

9. Institute of Cardiovascular Science and Medicine, the University of Hong Kong, Pokfulam, Hong Kong, China (BMYC)

Abbreviations:

ALM: appendicular lean mass

BF: body fat

BMI: body mass index

eGFR: estimated glomerular filtration rate

GWA: genome-wide association

HC: hip circumference

MR: Mendelian randomization

PRESSO test: Pleiotropy RESidual Sum and Outlier test

SNP: single nucleotide polymorphism

UNa: urinary sodium secretion

WC: waist circumference

WHR: waist-to-hip ratio

WLM: whole body lean mass

Abstract

Background: Observational studies have found associations between salt intake with obesity,

body shape and composition; but the findings may be biased by residual confounding.

Objective: To analyze the causal associations between salt intake and obesity measures in

both sex-combined and sex-specific models.

Designs: This was a two-sample Mendelian randomization study. Genome-wide association

(GWA) studies of urinary sodium secretion (UNa, a surrogate for salt intake), body mass

index (BMI), BMI-adjusted waist-to-hip ratio (WHR), body fat (BF) percentage and

estimated glomerular filtration rate (eGFR) were identified. We initially extracted fifty SNPs

associated with UNa at GWA significance level of 5×10^{-8}, but further removed those SNPs

with potential horizontal pleiotropy. Univariable MR and multivariable MR with adjustment

for eGFR were performed. Inverse-variance weighted MR was performed as the primary

analysis, with MR-Egger methods as sensitivity analysis. The potential bidirectional

association between BMI and UNa was investigated. All exposure and outcomes were

continuous, and the effect measure was linear regression coefficients (beta) and their 95%

confidence intervals (95%CI).

Results: UNa was causally associated with increased BMI in both men (eGFR-adjusted beta

0.443 (0.163 to 0.724)) and women (0.594 (0.333 to 0.855)). UNa caused BF percentage

increase in men (0.622 (0.268 to 0.976)) and women (0.334 (0.007 to 0.662)). UNa

significantly elevated BMI-adjusted WHR in men (0.321 (0.094 to 0.548)), but not in women

(0.170 (-0.052 to 0.391)). Additionally, we found that BMI causally increased UNa (0.043

(0.023 to 0.063)).

Conclusions: Salt intake increased BMI and BF percentage. Salt intake affects male body

shape by increasing BMI-adjusted WHR, but showed no effects on female body shape. The

bidirectional association between BMI and UNa suggested that salt reduction measures and

weight reduction measures should be implemented simultaneously to break the vicious cycle

and gain more health benefits.

Keywords: Urinary sodium; Salt intake; Obesity; Body fat mass; Mendelian randomization.

Introduction

Obesity has been a global public health concern with increasingly substantial disease burdens

(1–3). Obesity is believed to result from a complex relationship among psychosocial,

biological and behavioral factors, such as genetic susceptibility, excessive calorie intake and

physical inactivity (4). Other factors also contribute independently to development of obesity.

(4,5) Obesity, commonly measured with body mass index (BMI, body weight in

kilogram/squared height in meter), is a well-recognized risk factor for a range of health

conditions and diseases, including cardiovascular diseases (6), diabetes (7,8) and cancers (9–

11). BMI is easy to measure and calculate; nevertheless, body shape and body composition

are sometimes stronger predictors for health outcomes than BMI (12,13).

Dietary salt intake is known to be associated with disease conditions, such as blood pressure

(14), cardiovascular diseases (15), and diabetic complications (16). Salt intake can be

measured with food frequency questionnaire or estimated from urinary sodium secretion

(UNa), the latter of which is considered free of recall bias and more objective (17).

Observational studies have suggested its effect on obesity, independent of total energy intake

and fluid consumption. A systematic review published in 2015 (18) found that both dietary

salt intake and UNa were positively associated with BMI, although with substantial

heterogeneity. A recent cross-sectional study (19) showed that this positive association was

directionally concordant across Asian and Western populations, with varying effect sizes.

Another cross-sectional study (20) revealed an effect modified by sex, because the effect was

observed only in women but not men. Salt intake was also demonstrated to be correlated with

body shape and body composition measures, such as waist circumference (WC) (17,21),

waist-to-hip ratio (WHR, waist circumference/hip circumference) (17), body fat (BF) mass

and lean mass (20).

However, so far, the majority of the evidence has been generated from observational studies,

mainly cross-sectional studies, in which residual confounding and reverse causation are

likely. So far, few randomized trials on salt reduction have reported obesity-related outcomes

(22,23). Mendelian randomization (MR), by using single nucleotide polymorphisms (SNPs)

as instrumental variables to investigate the causal link between two phenotypes, is helpful in

causal inference (24). The objective of this study is to examine the causal association

between UNa with body mass, shape and composition using two-sample MR approach.

Materials and Methods

In this study, we used summary-level statistics from relevant GWA studies, where ethical

approval and patient consent had been obtained. The exposure of interest was UNa, a

commonly used surrogate marker for salt intake (25). The outcomes included BMI, body

shape and body composition. For body shape, we used BMI-adjusted WHR as the primary

outcome, while WC, hip circumference (HC), WHR, BMI-adjusted WC, BMI-adjusted HC

were secondary outcomes. For body composition, we used BF percentage as the primary

outcome, while whole-body lean mass (WLM) and appendicular lean mass (ALM) as

secondary outcomes. Since sex has been suggested as a potential effect modifier in obesity-

related outcomes (26–28), we investigated sex-specific effects in men and women separately

for the outcomes, if possible.

SNP selection

A GWA study of 446,237 European-ancestry individuals from UK Biobank (29) identified 50

lead SNPs associated with UNa that reached significance level of 5×10^{-8} (Supplementary

table 1). Spot urine sample collection and storage in UK Biobank have been described

elsewhere (30). UNa concentration was measured by the ion-selective electrode method. The

effect between genetic variants and log-transformed UNa concentration was adjusted for age,

sex, array information and ancestral principal components. The SNPs are located in different

gene regions and distributed independently (not in linkage disequilibrium), and explain 6.4%

of total variance of the trait (29). If an SNP could not be matched in the GWA studies of an

outcome, a proxy in linkage disequilibrium with the SNP ($R^2 > 0.80$) would be identified; if

no proper proxy was identified, the unmatched SNP would be removed from analysis.

Relevant traits associated with the SNPs were also searched in the PhenoScanner v2 database

at a significance level of 5×10^{-8} for potential pleiotropy.

Outcome data

We extracted relevant summary-level data of the outcomes from GWA studies of BMI (31),

body shape (32) and body composition (33,34). The BMI GWA study (31) included 322,154

European-ancestry individuals (152,882 men and 171,963 women) from 125 cohorts. The

effect was adjusted for age, squared age, ancestral principal components and study-specific

covariates. The body shape GWA study (32) included 211,088 European-ancestry individuals

(93,480 men and 116,742 women), and provided data for BMI-adjusted and unadjusted WC,

HC, and WHR, additionally adjusted for age, squared age and ancestral principal

components. The BF percentage GWA study (34) included 89,297 European-ancestry

individuals (44,429 men and 45,525 women), and was adjusted for age, squared age and

ancestral principal components. The GWA study for WLM and ALM (33) included 38,292

and 28,330 European-ancestry individuals, respectively, and was adjusted for age, sex,

squared age, height, body fat percentage and ancestral principal components. Body

composition (BF, WLM and ALM) was measured with either bioimpedance analysis or dual-

energy X-ray absorptiometry (32,33). Sex-combined and sex-specific outcome data were

available from the GWA studies of BMI, body shape and BF percentage. The GWA study for

WLM and ALM provided sex-combined data only.

Covariate

Renal function is associated with both UNa secretion (35) and obesity (36,37), which is a

potential confounder in the associations of interest. We identified a GWA study (38) of

estimated glomerular filtration rate (eGFR), which included 567,460 European-ancestry

individuals. Linear regression of log-transformed eGFR was adjusted for age, sex and

ancestry principal components.

Statistical analysis

Previous studies (29) have suggested that some of the UNa-associated SNPs are related to

adiposity phenotypes, which could introduce horizontal pleiotropy and violate one of the

underlying assumptions of MR. To minimize potential pleiotropy, we further removed SNPs

that: (1) were associated with the outcomes of interest at significance level of 5×10^{-8}, or (2)

were identified as outliers by the MR Pleiotropy RESidual Sum and Outlier (MR-PRESSO)

outlier tests (39). Therefore, the included SNPs for each outcome may differ but remained a

subset of the 50 SNPs identified by the UNa GWA study (29). Supplementary file 1 shows

the characteristics of the SNPs included in the MR analysis for each outcome. F statistic was

used to measure the strength of instrumental variables, and a F statistic > 10 suggests strong

instrument variables. (40)

All GWA summary-level data were harmonized with the method of Hartwig *et al*. (41), so

that the effect estimates of SNPs on exposure, outcome and covariate were shown for the

same alleles. Univariable MR analyses were performed with inverse-variance weighted

method as primary analysis, while weighted median method and MR-Egger regression

method as sensitivity analysis. Multivariable MR analyses adjusted for eGFR with inverse-

variance weighted method were performed as primary analysis, while MR-Egger method as

secondary analysis. The intercept test for MR-Egger regression was used to examine potential

residual horizontal pleiotropy, with a P value < 0.05 suggesting pleiotropy.

To investigate sex-specific effects, we extracted male-specific and female-specific outcome

data from the GWA studies, where applicable (31,32,34), and performed MR analyses

accordingly. Sex-specific effects on WLM and ALM were not estimated, because the data

were unavailable. To examine the effect difference between men and women, we performed a

heterogeneity test similar to that in meta-analysis, using Cochrane's Q test. A P-value for

Cochrane's Q test < 0.10 indicates statistical significance.

To investigate potential bidirectional association between UNa and BMI, we performed MR

analysis with BMI as the exposure and UNa as the outcome. Ninety-seven BMI-associated

SNPs were extracted from the BMI GWA study (31), but 84 SNPs were finally included after

removing those unmatched with UNa GWA data (29) and/or identified as outliers by the MR-

PRESSO outlier tests. Similarly, univariable and multivariable MR analyses were performed.

A second way to deal with potential confounding effect of eGFR, alternative to the

multivariable MR, was to remove the SNPs associated with eGFR. We found that rs1260326

(located in *GCKR* gene) was associated with eGFR at a GWA significance level of 5×10^{-8} in

Phenoscanner v2 database; therefore, a sensitivity analysis by removing rs1260326 in

univariable MR was performed as sensitivity analysis. Additional sensitivity analyses were

performed by including outlier SNPs detected by the MR-PRESSO outlier tests. Since all

outcomes were continuous, the effect measure was linear regression coefficient beta with its

95% confidence interval (CI), which should be interpreted as the change in units of standard

deviation (SD) in the outcome when the log-UNa level increases 1 SD. Statistical

significance was indicated by p value < 0.05. We did not apply Bonferroni correction,

although we employed three primary outcomes, because their effects were estimated from

three independent samples of individuals, instead of one. All statistical analysis was

conducted with "*MendelianRandomization*" (version 0.4.1) and "*MRPRESSO*" (version 1.0)

packages in R environment. **Supplementary figure 1** shows the flowchart of data selection

and analysis.

We planned to perform power calculations based on the method of Brion *et al*. (42), which

required the beta estimates from our study and another beta estimates from observational

analysis. However, the UNa GWA study analyzed log-UNa concentration (in log-mmol/L),

while previous observational studies analyzed UNa concentration in a natural unit (mmol/L)

or converted it to 24-hour UNa (mmol/d or g/d) or daily salt intake (g/d), thus making it

impossible to make direct comparisons of the two beta estimates in the absence of individual

participant data.

Results

The proportions of exposure variance explained by the instrument variables ranged from

4.036% to 5.565% (mean 4.780%), and the according F statistics ranged from 536.146 to

613.340 (mean 587.078), suggesting strong instrumental variables. (**Table** 1) Supplementary

file 1 showed detailed information on the SNPs included in the MR analysis for each

outcome.

Univariable MR

In sex-combined analyses, MR analyses with inverse-variance weighted method showed

positive causal associations between UNa with BMI (beta (95%CI): 0.392 (0.149 to 0.634);

Figure 1(A)), BMI-adjusted WHR (0.290 (0.101 to 0.478); **Figure 2**(A)) and BF percentage

(0.475 (0.208 to 0.741); **Figure 3**(A)). UNa was not associated with BMI-adjusted WC,

BMI-adjusted HC, WLM or ALM. MR-Egger intercept tests revealed no horizontal

pleiotropy. (Table 1)

BMI was positively related to UNa with the effect size of 0.042 (0.022 to 0.062), consistent

with the weighted median estimator (0.042 (0.019 to 0.066)). MR-Egger intercept test

showed no pleiotropy ($p = 0.119$). This suggested a bidirectional association between UNa

and BMI.

In men, UNa was positively associated with BMI (0.417 (0.113 to 0.720); Figure 1(B)), BMI-

adjusted WHR (0.339 (0.114 to 0.564); Figure 2(B)) and BF percentage (0.617 (0.270 to

0.963); Figure 3(B)), but negatively with BMI-adjusted HC (-0.396 (-0.699 to -0.092)). No

pleiotropy was observed according to MR-Egger intercept test, except WHR ($p = 0.029$),

which was a secondary outcome. UNa was associated with WC but not BMI-adjusted WC,

which suggested that BMI might mediate the association between UNa with WC. (Table 2)

In women, UNa increased BMI (0.571 (0.295 to 0.848); Figure 1(C)), BMI-adjusted WHR

(0.249 (0.027 to 0.472); Figure 2(C)) and BF percentage (0.348 (0.027 to 0.669); Figure

3(C)). UNa was associated with HC and WC, but the associations became insignificant after

adjustment for BMI. No pleiotropy was detected. (Table 1)

Multivariable MR

The results of multivariable MR analyses were largely consistent with the univariable

analyses. Overall, UNa was associated with increased BMI and BF percentage in both men

and women. Higher UNa affected male body shape by increasing BMI-adjusted WHR and

decreasing BMI-adjusted HC. UNa seemed to have little effects on female body shape after

adjusted for BMI and eGFR. Formal heterogeneity test showed significant difference

between men and women on BMI-adjusted HC, but not other outcomes. (**Table** 2) The

eGFR-adjusted effect of BMI on UNa was 0.043 (0.023 to 0.063) with no pleiotropy (p =

0.149), indicating a bidirectional association between BMI and UNa.

In sensitivity analysis including the SNPs that were identified as outliers by MR-PRESSO

outlier tests, both the univariable and multivariable MR showed results consistent with

primary results. (**Supplement table 2** and **supplementary table 3**) Removing the eGFR-

associated SNP rs1260326 also generated concordant results. (**Supplementary table 4**)

The scatter plots showed a potential outlier SNP rs4803378, located in gene *CTC-490E21.10*

and associated with urine creatinine according to PhenoScanner v2 database, the *post hoc*

sensitivity analyses by removing it showed similar results to the primary results.

(**Supplementary table 5**)

Discussion

In this MR study, salt intake, measured with UNa, was causally associated with increased

BMI and BF percentage. Higher salt intake changed body shape towards central obesity in

men, by reducing BMI-adjusted HC and increasing BMI-adjusted WHR, but probably not in

women. Additionally, salt intake and BMI were bidirectionally positively related.

These results were consistent with previous findings. Moosavian *et al.*(18) found in a meta-

analysis that both dietary salt intake and UNa were positively associated with BMI. This

study computed the effect measure as the mean difference of BMI between highest and

lowest categories of exposure, which introduced heterogeneity due to various cutoff values

used and made it difficult to directly compare the effect size with other studies. Zhou *et*

al.(19) found that for each 1gram per day (g/d) increase in salt intake, BMI increased by 0.42

and 0.52 kg/m^2, overweight/obesity risk increased by 29% and 24% in UK and US

population, respectively, after adjustment for total energy intake and physical activity. .

Salt intake showed an effect on body composition by increasing BF percentage, which is

consistent with previous findings. An increase of 1g/d salt intake was associated with an

increase of 0.91kg BF mass in UK population (21), and of 0.79kg BF mass and 0.44% BF

percentage in US population (20). Oh *et al*. (43) observed this positive association but only in

people under 65 years old. Zhu *et al*. (44) found salt intake was associated with increased BF

mass, BF percentage, and subcutaneous abdominal adipose tissue. Interestingly, a

randomized trial (45) found that low-salt diet significantly decreased body weight and

extracellular water, but reductions in BF mass and lean mass were insignificant. However,

this trial was limited by small sample size (84 obese people) and short follow-up period (2

months), which might make it underpowered to detect significant reductions. Salt intake has

an instant effect on water retention, but its effect on fat accumulation may take longer.

We found null effect of salt intake on lean mass, neither WLM nor ALM. This remains

uncertain. Previously, Ma *et al*. (21) showed that 1 g/d increase in salt intake was associated

with significant WLM increase by 0.32kg, but 1 g/2000kcal increase in salt intake density

insignificantly reduced WLM by 0.007kg. Zhang *et al*. (20) found that salt intake

significantly increased WLM by 0.53kg, but the effect became insignificant when using salt

intake density (g/kcal) to adjust for energy intake. It seems that there are two possible effects

of salt intake on body composition: (1) increase both fat and lean mass, but fat mass increases

at a higher rate; (2) increase fat mass solely. The first explanation was supported by the

findings that salt intake was associated with BF mass increase more than lean mass in both

UK (0.91kg versus 0.32kg for fat and lean mass increase, respectively) (21) and US

populations (0.79kg versus 0.53kg) (20). The second explanation was supported by the the

null effect of salt intake on lean mass after adjustment for energy intake (by using salt intake

density). (20,21) Our finding may also support the second explanation. Nevertheless, more

research is warranted on this topic.

There are several potential explanations for how salt intake affects body weight and

composition. It has been well recognized that excessive salt intake increases thirst and fluid

consumption, thus increasing extracellular water while keeping urine volume almost

unchanged. (46) Higher dietary salt intake also increases sweetened-beverage intake (47),

food appetite and calorie intake (18,48), which all contribute to weight gain. In addition, high

sodium intake has independent biological effects on fat accumulation. Lanaspa *et al*. (49)

demonstrated that high salt intake activated the aldose reductase-fructokinase pathway in

liver and hypothalamus, causing endogenous fructose production and the development of

leptin resistance and hyperphagia, which finally cause obesity. Fonseca-Alaniz *et al.* (50) also

observed that the high salt-induced adiposity in rats was characterized by high plasma leptin

concentrations and adipocyte hypertrophy, which might be mediated by lipogenic capacity of

white adipose mass. Lee *et al.* (51) revealed that high salt increased the expression of

adipogenic and lipogenic genes (such as *PPAR-γ, SREBP1c, ACC* and *C/EBPα*), but

decreased lipolysis gene expression (such as *AMPK*). However, its effect on lean mass

requires more replications and mechanism research.

We found that salt intake had an impact on body shape. Body shapes more predictive of

obesity-related mortality and health outcomes (52,53). Overall, salt intake increased both

BMI-adjusted and unadjusted WHR, leading to central obesity, which is in line with previous

findings (17,18,20,44). However, we observed an effect modification caused by sex. Salt

intake increased WHR in both sexes, but a significant increase in BMI-adjusted WHR was

seen in men only. Nam *et al.* (17) also found a similar sex difference. This may suggest that

salt intake affects body shape independent of BMI in men, but its effect on female body

shape is, at least partly, mediated by BMI.

This sexual dimorphism of body fat accumulation and distribution may be related to sex

hormones (26,54), sex chromosome (55) and sex-specific autosomal genetic heritability

(27,28,56,57). Estrogens favor fat accumulation in subcutaneous depot in women. Estrogens

and their receptor regulation also enhance the expandability of adipose cells in subcutaneous

depot and inhibits it in visceral depots. (26) Elevated free androgens have also been shown to

be related to increased abdominal visceral fat accumulation and increased WC. (58) The Four

Core Genotypes mouse model, has shown that X chromosome dosage is a risk factor for fat

accumulation, but the presence of Y chromosome is not (56). Other studies have also shown

that that adipocytes from different subcutaneous depots (abdominal versus gluteal) are

developmentally distinct in a sex-dependent manner (59,60). The GWA study of BMI-

adjusted WHR showed a higher heritability in women than in men (2.4% versus 0.8%) (32).

This indicates that male body shape is more likely to be influenced by environmental factors

(56), such as salt intake. However, mechanistic studies are needed to elucidate this issue.

In this MR study, we observed that high BMI was causally linked to higher UNa. High UNa

could be resulted from two possible mechanisms: obesity-related glomerulopathy and high

salt intake. Obesity is known to increase risk of glomerulopathy, characterized with altered

renal hemodynamics, increased eGFR and tubular sodium reabsorption (61); however, the

overall effect of glomerulopathy on UNa remains unclear. On the other hand, in our study,

the association between BMI and UNa remained significant after adjustment for renal

function , therefore, we believe that salt intake has independent mediation effect on the

association between BMI and UNa, that is, BMI increases UNa by increasing salt intake,

independent of renal function. Li *et al*. (62) found that overweight/obese people had lower

salt sensitivity and higher salt preference, and consumed 2.3g/d more dietary salt than

normal-weight people

The bidirectional association between obesity and salt intake indicates the formation of a

vicious cycle, in which people with higher BMI are prone to consume more salt, which then

further increases their BMI. Considering that high salt intake and obesity, both prevalent

worldwide, are shared risk factors for many chronic diseases and that they also have their

own adverse health consequences (63), urgent interventions are required to break this cycle in

high-risk individuals.

Salt reduction and weight reduction programs have been widely implemented in various

settings, but separately. Salt reduction programs do not consider weight change as an

outcome, while weight reduction programs pay little emphasis on salt reduction measures.

We are not advocating weight control by salt reduction alone. Instead, our findings provide

evidence to combine salt reduction and weight reduction measures, to facilitate people to

acquire a healthier lifestyle and achieve higher health benefits. Although the actual effect size

of salt reduction on weight reduction has not been precisely estimated yet, which warrants

future well-designed randomized trials, salt reduction *per se* costs less and brings additional

health benefits. (22,43,64)

There are some limitations. First, we did not include all identified UNa-associated SNPs

because unmatched data and pleiotropy issues; however, our results are consistent in primary

analyses and sensitivity analyses, and with previous studies. Second, more accurate

measurement of UNa is via 24-hour urine sample collection, but the UK Biobank uses spot

urine sample. The 24-hour urine collection method is more expensive, time-consuming,

labor-intensive and difficult for an epidemiological study as large as UK Biobank with half a

million participants. Previous studies showed that spot UNa is an acceptable surrogate for 24-

hour UNa and dietary salt intake, and has been commonly employed elsewhere (25,30).

Third, there might still be residual pleiotropy, although we have removed SNPs that were

significantly associated with outcomes and that were identified as outliers by the MR-

PRESSO outlier test. MR-Egger intercept test showed pleiotropy for a few secondary

outcomes (e.g., HC, WC) only. Fourth, the effect size estimated in this study was not directly

comparable to other studies in which the effect was measured at natural units of outcome by

1 g/d salt intake increase. Although several equations have been proposed to estimate salt

intake in g/d from 24h urine sodium secretion in g/d or spot urine sodium concentration in

mmol/L (25), the UNa GWA study log-transformed the original spot UNa concentration,

which makes back-transformation of beta estimate to natural unit impossible. Due to the

same reason, formal power calculations were not performed as we planned, which was

another limitation, but our study has employed strong instrumental variables and so far the

largest GWA studies available. Lastly, we only included European-ancestry population, thus

generalizing the results to other ethnicities requires cautions.

Conclusion

Salt intake increases BMI and BF percentage, and changes male body shape towards central

obesity by increasing BMI-adjusted WHR. Given the bidirectional association between salt

intake and obesity, salt reduction measures and weight reduction measures should be

implemented together to achieve more health benefits.

400   **Acknowledgement**

401   **Conflict of interest:** None.

403   **Ethical approval**: Not required.

405   **Data sharing**: Data described in the manuscript, code book and analytic code will be made

406   available upon request.

Reference

1. Tremmel M, Gerdtham UG, Nilsson PM, Saha S. Economic burden of obesity: a systematic literature review. Int J Environ Res Public Health. 2017;14.

2. Seidell JC, Halberstadt J. The global burden of obesity and the challenges of prevention. Ann Nutr Metab. 2015;66:7–12.

3. Arroyo-Johnson C, Mincey KD. Obesity epidemiology worldwide. Gastroenterol Clin North Am. 2016;45:571–9.

4. Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. 2016;22:s176-85.

5. Lee EY, Yoon KH. Epidemic obesity in children and adolescents: risk factors and prevention. Front Med. 2018;12:658–66.

6. Ortega FB, Lavie CJ, Blair SN. Obesity and cardiovascular disease. Circ Res. 2016;118:1752–70.

7. Malone JI, Hansen BC. Does obesity cause type 2 diabetes mellitus (T2DM)? Or is it the opposite? Pediatr Diabetes. 2019;20:5–9.

8. Wei J, Liu X, Xue H, Wang Y, Shi Z. Comparisons of visceral adiposity index, body shape index, body mass index and waist circumference and their associations with diabetes mellitus in adults. Nutrients. 2019;11.

9. Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism. 2019;92:121–35.

10. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013;2013:291546.

11. Gunter MJ, Riboli E. Obesity and gastrointestinal cancers - where do we go from here? Nat Rev Gastroenterol Hepatol. 2018;15:651–2.

12. Chen G-C, Arthur R, Iyengar NM, Kamensky V, Xue X, Wassertheil-Smoller S, Allison MA, Shadyab AH, Wild RA, Sun Y, et al. Association between regional body fat and cardiovascular disease risk among postmenopausal women with normal body mass index. Eur Heart J. 2019;40:2849–55.

13. Huxley R, Mendis S, Zheleznyakov E, Reddy S, Chan J. Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular risk--a review of the literature. Eur J Clin Nutr. 2010;64:16–22.

14. Rust P, Ekmekcioglu C. Impact of salt intake on the pathogenesis and treatment of hypertension. Adv Exp Med Biol. 2017;956:61–84.

15. Meneton P, Jeunemaitre X, de Wardener HE, MacGregor GA. Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases. Physiol Rev. 2005;85:679–715.

16. Horikawa C, Sone H. Dietary salt intake and diabetes complications in patients with diabetes: An overview. J Gen Fam Med. 2017;18:16–20.

17. Nam GE, Kim SM, Choi MK, Heo YR, Hyun TS, Lyu ES, Oh SY, Park HR, Ro HK, Han K, et al. Association between 24-h urinary sodium excretion and obesity in Korean adults: A multicenter study. Nutrition. 2017;41:113–9.

18. Moosavian SP, Haghighatdoost F, Surkan PJ, Azadbakht L. Salt and obesity: a systematic review and meta-analysis of observational studies. Int J Food Sci Nutr. 2017;68:265–77.

19. Zhou L, Stamler J, Chan Q, Van Horn L, Daviglus ML, Dyer AR, Miura K, Okuda N, Wu Y, Ueshima H, et al. Salt intake and prevalence of overweight/obesity in Japan, China, the United Kingdom, and the United States: the INTERMAP Study. Am J Clin Nutr. 2019;110:34–40.

20. Zhang X, Wang J, Li J, Yu Y, Song Y. A positive association between dietary sodium intake and obesity and central obesity: results from the National Health and Nutrition Examination Survey 1999-2006. Nutr Res. 2018;55:33–44.

21. Ma Y, He FJ, MacGregor GA. High salt intake: independent risk factor for obesity? Hypertension. 2015;66:843–9.

22. He FJ, Li J, MacGregor GA. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ. 2013;346:f1325–f1325.

23. Hyseni L, Elliot-Green A, Lloyd-Williams F, Kypridemos C, O'Flaherty M, McGill R, Orton L, Bromley H, Cappuccio FP, Capewell S. Systematic review of dietary salt reduction policies: Evidence for an effectiveness hierarchy? PloS One. 2017;12:e0177535.

24. Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. JAMA. 2017;318:1925–6.

25. Huang L, Crino M, Wu JHY, Woodward M, Barzi F, Land M-A, McLean R, Webster J, Enkhtungalag B, Neal B. Mean population salt intake estimated from 24-h urine samples and spot urine samples: a systematic review and meta-analysis. Int J Epidemiol. 2016;45:239–50.

26. Palmer BF, Clegg DJ. The sexual dimorphism of obesity. Mol Cell Endocrinol. 2015;402:113–9.

27. Rask-Andersen M, Karlsson T, Ek WE, Johansson A. Genome-wide association study of body fat distribution identifies adiposity loci and sex-specific genetic effects. Nat Commun. 2019;10:339.

28. Winkler TW, Justice AE, Graff M, Barata L, Feitosa MF, Chu S, Czajkowski J, Esko T, Fall T, Kilpelainen TO, et al. The influence of age and sex on genetic associations with adult body size and shape: A large-scale genome-wide interaction study. PLoS Genet. 2015;11:e1005378.

29. Pazoki R, Evangelou E, Mosen-Ansorena D, Pinto RC, Karaman I, Blakeley P, Gill D, Zuber V, Elliott P, Tzoulaki I, et al. GWAS for urinary sodium and potassium excretion highlights pathways shared with cardiovascular traits. Nat Commun. 2019;10:3653.

30. Welsh CE, Welsh P, Jhund P, Delles C, Celis-Morales C, Lewsey JD, Gray S, Lyall D, Iliodromiti S, Gill JMR, et al. Urinary sodium excretion, blood pressure, and risk of future cardiovascular disease and mortality in subjects without prior cardiovascular disease. Hypertens Dallas Tex 1979. 2019;73:1202–9.

31. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich ML, Yang J, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518:197–206.

32. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Magi R, Strawbridge RJ, Pers TH, Fischer K, Justice AE, et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015;518:187–96.

33. Zillikens MC, Demissie S, Hsu YH, Yerges-Armstrong LM, Chou WC, Stolk L, Livshits G, Broer L, Johnson T, Koller DL, et al. Large meta-analysis of genome-wide association studies identifies five loci for lean body mass. Nat Commun. 2017;8:80.

34. Lu Y, Day FR, Gustafsson S, Buchkovich ML, Na J, Bataille V, Cousminer DL, Dastani Z, Drong AW, Esko T, et al. New loci for body fat percentage reveal link between adiposity and cardiometabolic disease risk. Nat Commun. 2016;7:10495.

35. Nomura K, Asayama K, Jacobs L, Thijs L, Staessen JA. Renal function in relation to sodium intake: a quantitative review of the literature. Kidney Int. 2017;92:67–78.

36. Jamshidi P, Najafi F, Mostafaei S, Shakiba E, Pasdar Y, Hamzeh B, Moradinazar M. Investigating associated factors with glomerular filtration rate: structural equation modeling. BMC Nephrol. 2020;21:30.

37. Whaley-Connell A, Sowers JR. Obesity and kidney disease: from population to basic science and the search for new therapeutic targets. Kidney Int. 2017;92:313–23.

38. Wuttke M, Li Y, Li M, Sieber KB, Feitosa MF, Gorski M, Tin A, Wang L, Chu AY, Hoppmann A, et al. A catalog of genetic loci associated with kidney function from analyses of a million individuals. Nat Genet. 2019;51:957–72.

39. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50:693–8.

40. Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol. 2011;40:740–52.

41. Hartwig FP, Davies NM, Hemani G, Davey Smith G. Two-sample Mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique. Int J Epidemiol. 2016;45:1717–26.

42. Brion M-JA, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol. 2013;42:1497–501.

43. Oh SW, Koo HS, Han KH, Han SY, Chin HJ. Associations of sodium intake with obesity, metabolic disorder, and albuminuria according to age. PloS One. 2017;12:e0188770.

44. Zhu H, Pollock NK, Kotak I, Gutin B, Wang X, Bhagatwala J, Parikh S, Harshfield GA, Dong Y. Dietary sodium, adiposity, and inflammation in healthy adolescents. Pediatrics. 2014;133:e635-642.

45. Kang HJ, Jun DW, Lee SM, Jang EC, Cho YK. Low salt and low calorie diet does not reduce more body fat than same calorie diet: a randomized controlled study. Oncotarget. 2018;9:8521–30.

46. Bankir L, Perucca J, Norsk P, Bouby N, Damgaard M. Relationship between sodium intake and water intake: the false and the true. Ann Nutr Metab. 2017;70 Suppl 1:51–61.

47. Grimes CA, Riddell LJ, Campbell KJ, Nowson CA. Dietary salt intake, sugar-sweetened beverage consumption, and obesity risk. Pediatrics. 2013;131:14–21.

48. Bolhuis DP, Costanzo A, Newman LP, Keast RS. Salt promotes passive overconsumption of dietary fat in humans. J Nutr. 2016;146:838–45.

49. Lanaspa MA, Kuwabara M, Andres-Hernando A, Li N, Cicerchi C, Jensen T, Orlicky DJ, Roncal-Jimenez CA, Ishimoto T, Nakagawa T, et al. High salt intake causes leptin resistance and obesity in mice by stimulating endogenous fructose production and metabolism. Proc Natl Acad Sci U A. 2018;115:3138–43.

50. Fonseca-Alaniz MH, Brito LC, Borges-Silva CN, Takada J, Andreotti S, Lima FB. High dietary sodium intake increases white adipose tissue mass and plasma leptin in rats. Obes Silver Spring. 2007;15:2200–8.

51. Lee M, Sorn SR, Lee Y, Kang I. Salt induces adipogenesis/lipogenesis and inflammatory adipocytokines secretion in adipocytes. Int J Mol Sci. 2019;20(1):pii.

52. Fu J, Hofker M, Wijmenga C. Apple or pear: size and shape matter. Cell Metab. 2015;21:507–8.

53. Golzarri-Arroyo L, Mestre LM, Allison DB. What's new in understanding the risk associated with body size and shape?: pears, apples, and olives on toothpicks. JAMA Netw Open. 2019;2:e197336.

54. Valencak TG, Osterrieder A, Schulz TJ. Sex matters: The effects of biological sex on adipose tissue biology and energy metabolism. Redox Biol. 2017;12:806–13.

55. Zore T, Palafox M, Reue K. Sex differences in obesity, lipid metabolism, and inflammation-A role for the sex chromosomes? Mol Metab. 2018;15:35–44.

56. Link JC, Reue K. Genetic basis for sex differences in obesity and lipid metabolism. Annu Rev Nutr. 2017;37:225–45.

57. Pulit SL, Karaderi T, Lindgren CM. Sexual dimorphisms in genetic loci linked to body fat distribution. Biosci Rep. 2017;37.

58. Blouin K, Boivin A, Tchernof A. Androgens and body fat distribution. J Steroid Biochem Mol Biol. 2008;108:272–80.

59. Fried SK, Lee M-J, Karastergiou K. Shaping fat distribution: New insights into the molecular determinants of depot- and sex-dependent adipose biology. Obes Silver Spring Md. 2015;23:1345–52.

60. Karastergiou K, Fried SK, Xie H, Lee M-J, Divoux A, Rosencrantz MA, Chang RJ, Smith SR. Distinct developmental signatures of human abdominal and gluteal subcutaneous adipose tissue depots. J Clin Endocrinol Metab. 2013;98:362–71.

61. D'Agati VD, Chagnac A, de Vries APJ, Levi M, Porrini E, Herman-Edelstein M, Praga M. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol. 2016;12:453–71.

62. Li Q, Jin R, Yu H, Lang H, Cui Y, Xiong S, Sun F, He C, Liu D, Jia H, et al. Enhancement of neural salty preference in obesity. Cell Physiol Biochem. 2017;43:1987–2000.

63. Cheung BMY, Li C. Diabetes and hypertension: is there a common metabolic pathway? Curr Atheroscler Rep. 2012;14:160–6.

64. Hoffmann IS, Cubeddu LX. Salt and the metabolic syndrome. Nutr Metab Cardiovasc Dis NMCD. 2009;19:123–8.

Table 1. Results of univariable Mendelian randomization analyses of sex-combined and sex-specific association between urinary sodium secretion with body mass, shape and composition outcomes.

Outcome	SNPs	N	R^2 (%)	F statistic	Inverse-variance weighed method		Weighted median methods		MR-Egger method		
					Beta (95% CI)	p for beta	Beta (95% CI)	p for beta	Beta (95% CI)	p for beta	p for Egger intercept
Sex-combined											
BMI	34	322154	4.227	579.157	0.392 (0.149, 0.634)	0.002	0.542 (0.287, 0.797)	<0.001	-0.193 (-1.387, 1.001)	0.751	0.327
HC	35	211088	4.036	536.146	0.247 (-0.014, 0.509)	0.064	0.215 (-0.080, 0.510)	0.153	-0.286 (-1.703, 1.131)	0.693	0.453
WC	37	211088	4.546	574.298	0.508 (0.228, 0.789)	<0.001	0.526 (0.231, 0.822)	<0.001	-0.041 (-1.452, 1.370)	0.954	0.436
WHR	38	211088	4.703	579.443	0.449 (0.220, 0.677)	<0.001	0.511 (0.241, 0.780)	<0.001	-0.072 (-1.256, 1.111)	0.905	0.379
BMI-adjusted HC	39	211088	4.953	596.237	-0.122 (-0.289, 0.046)	0.154	-0.102 (-0.347, 0.144)	0.417	0.305 (-0.519, 1.130)	0.468	0.300
BMI-adjusted WC	43	211088	5.565	611.484	0.136 (-0.045, 0.317)	0.140	0.110 (-0.115, 0.336)	0.338	0.610 (-0.266, 1.486)	0.173	0.279
BMI-adjusted WHR	40	211088	5.089	598.136	0.290 (0.101, 0.478)	0.003	0.310 (0.087, 0.532)	0.006	0.379 (-0.636, 1.394)	0.464	0.861
BF percentage	41	89297	5.207	597.795	0.475 (0.208, 0.741)	<0.001	0.335 (-0.008, 0.679)	0.055	0.028 (-1.309, 1.365)	0.967	0.504
WLM	40	38292	4.942	579.909	0.639 (-0.579, 1.857)	0.304	0.831 (-0.832, 2.495)	0.327	-3.710 (-10.054, 2.634)	0.252	0.171
ALM	40	28330	4.942	579.909	-0.233 (-1.008, 0.542)	0.556	0.034 (-1.017, 1.086)	0.949	-3.363 (-7.259, 0.533)	0.091	0.108
Male-specific											
BMI	38	152882	4.731	583.146	0.417 (0.113, 0.720)	0.007	0.610 (0.289, 0.931)	<0.001	0.378 (-1.117, 1.874)	0.620	0.959
HC	37	93480	4.522	571.095	0.197 (-0.155, 0.549)	0.272	0.196 (-0.193, 0.584)	0.323	1.451 (-0.394, 3.297)	0.123	0.175
WC	35	93480	4.299	572.741	0.476 (0.157, 0.796)	0.003	0.584 (0.175, 0.993)	0.005	0.646 (-1.078, 2.370)	0.463	0.844
WHR	38	93480	4.775	588.810	0.607 (0.315, 0.899)	<0.001	0.399 (0.043, 0.755)	0.028	-1.013 (-2.499, 0.472)	0.181	0.029
BMI-adjusted HC	38	93480	4.723	582.123	-0.396 (-0.699, -0.092)	0.011	-0.252 (-0.625, 0.120)	0.184	0.727 (-0.848, 2.303)	0.366	0.155
BMI-adjusted WC	40	93480	5.133	603.571	0.097 (-0.135, 0.329)	0.411	0.015 (-0.313, 0.344)	0.927	0.802 (-0.382, 1.987)	0.184	0.234
BMI-adjusted WHR	40	93480	5.133	603.571	0.339 (0.114, 0.564)	0.003	0.230 (-0.076, 0.536)	0.141	-0.332 (-1.489, 0.824)	0.574	0.246
BF percentage	41	44429	5.207	597.795	0.617 (0.270, 0.963)	<0.001	0.134 (-0.322, 0.590)	0.564	-0.410 (-2.117, 1.298)	0.638	0.229

Female-specific

BMI	36	171963	4.452	577.461	0.571 (0.295, 0.848)	<0.001	0.552 (0.243, 0.860)	<0.001	0.011 (-1.421, 1.443)	0.988	0.434
HC	37	116742	4.669	590.581	0.455 (0.157, 0.752)	0.003	0.492 (0.168, 0.815)	0.003	0.747 (-0.877, 2.371)	0.367	0.720
WC	33	116742	4.249	600.039	0.480 (0.190, 0.769)	0.001	0.46 (0.125, 0.795)	0.007	-0.030 (-1.558, 1.498)	0.969	0.505
WHR	37	116742	4.602	581.688	0.395 (0.115, 0.676)	0.006	0.501 (0.196, 0.805)	0.001	0.742 (-0.825, 2.309)	0.353	0.659
BMI-adjusted HC	38	116742	4.822	594.864	-0.032 (-0.239, 0.176)	0.766	-0.096 (-0.384, 0.192)	0.514	0.597 (-0.488, 1.681)	0.281	0.248
BMI-adjusted WC	40	116742	5.212	613.340	0.190 (-0.027, 0.406)	0.085	0.288 (-0.001, 0.576)	0.050	0.528 (-0.585, 1.642)	0.352	0.544
BMI-adjusted WHR	38	116742	4.659	573.819	0.249 (0.027, 0.472)	0.028	0.264 (-0.028, 0.556)	0.076	1.057 (-0.185, 2.298)	0.095	0.196
BF percentage	42	45525	5.319	596.862	0.348 (0.027, 0.669)	0.034	0.414 (-0.010, 0.838)	0.056	0.724 (-0.882, 2.330)	0.377	0.639

BMI: body mass index. WC: waist circumference. HC: hip circumference. WHR: waist-to-hip ratio. BF: body fat. ALM: appendicular lean mass. WLM: whole body lean mass. SNP: single nucleotide polymorphism. R^2(%): the percentage of exposure variance explained by SNPs. 95% CI: 95% confidence interval.

Table 2: Results of multivariable Mendelian randomization analysis (inverse-variance weighted method) adjusted for estimated glomerular filtration rate

| Outcome | SNPs | N | R^2 (%) | F statistic | Inverse-variance weighted method | | MR-Egger method | | | |
					Beta (95%CI)	p for beta	Beta (95%CI)	p for beta	P for Egger intercept	p for heterogeneity between sexes
Sex-combined										
BMI	34	322154	4.227	579.157	0.406 (0.202, 0.610)	<0.001	0.319 (-0.736, 1.373)	0.554	0.868	0.439
HC	35	211088	4.036	536.146	0.299 (0.055, 0.544)	0.017	0.449 (-0.998, 1.896)	0.543	0.837	0.768
WC	37	211088	4.546	574.298	0.533 (0.283, 0.783)	<0.001	0.486 (-0.821, 1.794)	0.466	0.943	0.359
WHR	38	211088	4.703	579.443	0.385 (0.145, 0.624)	0.002	-0.371 (-1.567, 0.825)	0.543	0.207	0.225
BMI-adjusted HC	39	211088	4.953	596.237	-0.094 (-0.259, 0.070)	0.261	0.277 (-0.523, 1.078)	0.497	0.353	0.073
BMI-adjusted WC	43	211088	5.565	611.484	0.121 (-0.045, 0.287)	0.154	0.719 (-0.078, 1.516)	0.077	0.133	0.723
BMI-adjusted WHR	40	211088	5.089	598.136	0.222 (0.029, 0.416)	0.025	0.052 (-0.979, 1.083)	0.921	0.742	0.351
BF percentage	41	89297	5.207	597.795	0.471 (0.198, 0.744)	0.001	0.024 (-1.331, 1.379)	0.972	0.509	0.242
WLM	40	38292	4.942	579.909	0.633 (-0.587, 1.853)	0.309	-3.705 (-10.074, 2.665)	0.254	0.174	NA
ALM	40	28330	4.942	579.909	-0.246 (-1.029, 0.536)	0.537	-3.276 (-7.231, 0.679)	0.104	0.126	NA
Male-specific										
BMI	38	152882	4.731	583.146	0.443 (0.163, 0.724)	0.002	0.755 (-0.650, 2.159)	0.292	0.657	
HC	37	93480	4.522	571.095	0.228 (-0.102, 0.557)	0.176	2.204 (0.492, 3.915)	0.012	0.021	
WC	35	93480	4.299	572.741	0.526 (0.238, 0.813)	<0.001	1.335 (-0.241, 2.911)	0.097	0.306	
WHR	38	93480	4.775	588.810	0.598 (0.300, 0.896)	<0.001	-1.020 (-2.522, 0.482)	0.183	0.032	
BMI-adjusted HC	38	93480	4.723	582.123	-0.368 (-0.673, -0.063)	0.018	0.693 (-0.879, 2.266)	0.388	0.178	
BMI-adjusted WC	40	93480	5.133	603.571	0.079 (-0.156, 0.314)	0.508	0.784 (-0.402, 1.969)	0.195	0.235	
BMI-adjusted WHR	40	93480	5.133	603.571	0.321 (0.094, 0.548)	0.006	-0.346 (-1.503, 0.811)	0.557	0.249	
BF percentage	41	44429	5.207	597.795	0.622 (0.268, 0.976)	0.001	-0.406 (-2.135, 1.323)	0.645	0.234	
Female-specific										
BMI	36	171963	4.452	577.461	0.594 (0.333, 0.855)	<0.001	0.361 (-1.034, 1.755)	0.612	0.739	

HC	37	116742	4.669	590.581	0.437 (0.135, 0.739)	0.005	0.710 (-0.926, 2.345)	0.395	0.740
WC	33	116742	4.249	600.039	0.464 (0.170, 0.758)	0.002	-0.053 (-1.592, 1.485)	0.946	0.502
WHR	37	116742	4.602	581.688	0.337 (0.039, 0.636)	0.027	0.471 (-1.184, 2.125)	0.577	0.872
BMI-adjusted HC	38	116742	4.822	594.864	-0.028 (-0.240, 0.184)	0.796	0.598 (-0.501, 1.697)	0.286	0.256
BMI-adjusted WC	40	116742	5.212	613.340	0.135 (-0.067, 0.336)	0.190	0.430 (-0.594, 1.453)	0.411	0.564
BMI-adjusted WHR	38	116742	4.659	573.819	0.170 (-0.052, 0.391)	0.133	0.702 (-0.534, 1.938)	0.266	0.391
BF percentage	42	45525	5.319	596.862	0.334 (0.007, 0.662)	0.045	0.713 (-0.908, 2.334)	0.388	0.640

BMI: body mass index. WC: waist circumference. HC: hip circumference. WHR: waist-to-hip ratio. BF: body fat. ALM: appendicular lean mass. WLM: whole body lean mass. SNP: single nucleotide polymorphism. R^2(%): the percentage of exposure variance explained by SNPs. 95% CI: 95% confidence interval. NA: not applicable.

Figure 1

Figure 2

Figure 3

Figure legends

Figure 1: Scatter plots for Mendelian randomization analysis of urinary sodium and BMI.

(A) sex-combined, (B) male-specific, (C) female-specific. Horizontal axis: SNPs' association with urinary sodium. Vertical axis: SNPs' association with BMI. The fitted line showed the results of the inverse-variance weighted method in univariable MR.

Figure 2: Scatter plots for Mendelian randomization analysis of urinary sodium and BMI-adjusted waist-to-hip ratio.

(A) sex-combined, (B) male-specific, (C) female-specific. Horizontal axis: SNPs' association with urinary sodium. Vertical axis: SNPs' association with BMI-adjusted waist-to-hip ratio. The fitted line showed the results of the inverse-variance weighted method in univariable MR.

Figure 3: Scatter plots for Mendelian randomization analysis of urinary sodium and body fat percentage.

(A) sex-combined, (B) male-specific, (C) female-specific. Horizontal axis: SNPs' association with urinary sodium. Vertical axis: SNPs' association with body fat percentage. The fitted line showed the results of the inverse-variance weighted method in univariable MR.